Statins and cancer prevention

Nature Reviews Cancer

Volumn 5, Issue 12, 2005, Pages 930-942

  Demierre, Marie France ^a   Higgins, Peter D R ^b   Gruber, Stephen B ^b   Hawk, Ernest ^c   Lippman, Scott M ^d  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; BEZAFIBRATE; CELECOXIB; CERIVASTATIN; COLESTYRAMINE; COMPACTIN; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MEVALONIC ACID; MEVINOLIN; NICOTINIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PERILLYL ALCOHOL; PRAVASTATIN; RHO FACTOR; RHO KINASE INHIBITOR; SIMVASTATIN; SQUALENE; SULINDAC;

ANGIOGENESIS; APOPTOSIS; BREAST CANCER; CANCER PREVENTION; CANCER RISK; CARDIOVASCULAR DISEASE; CELL PROLIFERATION; CLINICAL TRIAL; COLORECTAL CANCER; DISEASE EXACERBATION; DRUG ACTIVITY; DRUG EFFECT; HUMAN; MELANOMA; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN FUNCTION; REVIEW; RISK REDUCTION; SIGNAL TRANSDUCTION; STRUCTURE ANALYSIS;

ANIMALS; APOPTOSIS; BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; COLORECTAL NEOPLASMS; DISEASE MODELS, ANIMAL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN-1; MELANOMA; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RANDOMIZED CONTROLLED TRIALS;

EID: 28844490054     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc1751     Document Type: Review

References (127)

1. Oliver, M. F. Might treatment of hypercholesterolaemia increase non-cardiac mortality? Lancet 337, 1529-1531 (1991).
2. Newman, T. B. & Hulley, S. B. Carcinogenicity of lipid-lowering drugs. JAMA 275, 55-60 (1996).
3. Ridker, P. M. et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) investigators. Circulation 98, 839-844 (1998). Important early report indicating that statins can have cholesterol-independent effects - such as anti-inflammatory effects that are proving to be important in CVD, cancer and other disease settings - in addition to well-known HMG-CoA reductase-dependent and cholesterol-dependent effects.
4. Gotto, A. M. Jr et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation 101, 477-484 (2000).
5. Ehrenstein, M. R., Jury, E. C. & Mauri, C. Statins for atherosclerosis - as good as it gets? N. Engl. J. Med. 352, 73-75 (2005).
6. Chan, K. K. W., Oza, A. M. & Siu, L. L. The statins as anticancer agents. Clin. Cancer Res. 9, 10-19 (2003).
7. Wong, W. W. L., Dimitroulakos, J., Minden, M. D. & Penn, L. Z. HMB-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia 16, 508-519 (2002).
8. Edwards, P. A. & Ericsson, J. Sterols and isoprenoids: signaling molecules derived from the cholesterol biosynthetic pathway. Annu. Rev. Biochem. 68, 157-185 (1999).
9. Houten, S. M., Frenkel, J. & Waterham, H. R. Isoprenoid biosynthesis in hereditary periodic fever syndromes and inflammation. Cell. Mol. Life Sci. 60, 1118-1134 (2003).
10. Mo, H. & Elson, C. E. Studies of the isoprenoid-mediated inhibition of mevalonate synthesis applied to cancer chemotherapy and chemoprevention. Exp. Biol. Med. 229, 567-585 (2004).
11. Simpson, K. J., Dugan, A. S. & Mercurio, A. M. Functional analysis of the contribution of RhoA and RhoC GTPases to invasive breast carcinoma. Cancer Res. 64, 8694-8701 (2004).
12. Kusama, T. et al. Inhibition of epidermal growth factor-induced RhoA translocation and invasion of human pancreatic cancer cells by 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. Cancer Res. 61, 4885-4891 (2001).
13. Malliri, A. & Collard, J. G. Role of Rho-family proteins in cell adhesion and cancer. Curr. Opin. Cell Biol. 15, 583-589 (2003).
14. Zugaza, J. L., Caloca, M. J. & Bustelo X. R. Inverted signaling hierarchy between RAS and RAC in T-lymphocytes. Oncogene 23, 5823-5833 (2004).
15. Mazieres, J. et al. Geranylgeranylated, but not farnesylated, RhoB suppresses Ras transformation of NIH-3T3 cells. Exp. Cell. Res. 304, 354-364 (2005).
16. Singh, A. et al. Rac1b, a tumor associated, constitutively active Rac1 splice variant, promotes cellular transformation. Oncogene 23, 9369-9380 (2004).
17. Gerber, J. G. et al. Effect of Efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS clinical trials group 5108 study. J. Acquir. Immune Defic. Syndr. 39, 307-312 (2005).
18. Buemi, M. et al. Pro-apoptotic effect of fluvastatin on human smooth muscle cells. Eur. J. Pharmacol. 370, 201-203 (1999).
19. Weitz-Schmidt, G. et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nature Med. 7, 687-692 (2001). First clear example of an HMG-CoA reductase-independent effect of statins and a mechanism (binding to LFA1) for this effect. This work shows that lovastatin directly binds to the L-site in the I-domain of the integrin LFA1, which has an important role in leukocyte migration and T-cell activation. These findings indicate that a new class of anti-inflammatory agents could be developed (see reference 122).
20. Katano, H., Pesnicak, L. & Cohen, J. I. Simvastatin induces apoptosis of Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines and delays development of EBV lymphomas. Proc. Natl Acad. Sci. USA 101, 4960-4965 (2004).
21. Rao, S. et al. Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase. Proc. Natl Acad. Sci. USA 96, 7797-7802 (1999).
22. Ukomadu, C. & Dutta, A. p21-dependent inhibition of colon cancer cell growth by mevastatin is independent of inhibition of G1 cyclin-dependent kinases. J. Biol. Chem. 278, 43586-43594 (2003).
23. Veillard, N. R. & Mach, F. Statins: the new aspirin? Cell. Mol. Life Sci. 59, 1771-1786 (2002).
24. Youssef, S. et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 420, 78-84 (2002).
25. Hilgendorff, A. et al. Statins differ in their ability to block NF-κB activation in human blood monocytes. Intl J. Clin. Pharmacol. Ther. 41, 397-401 (2003).
26. Hakamada-Taguchi, R. et al. Inhibition of hydroxymethylglutaryl-coenzyme a reductase reduces Th1 development and promotes Th2 development. Circ. Res. 93, 948-956 (2003).
27. Tilkin-Mariame, A. F. et al. Geranylgeranyl transferase inhibition stimulates antimelanoma immune response through MHC class I and costimulatory molecule expression. FASEB J. 29 Jun 2005 (doi:10.1096/fj.04-3482fje).
28. Weis, M., Heeschen, C., Glassford, A. J. & Cooke, J. P. Statins have biphasic effects on angiogenesis. Circulation 105, 739-745 (2002).
29. Sata, M. et al. Statins augment collateral growth in response to ischemia but they do not promote cancer and atherosclerosis. Hypertension 43, 1214-1220 (2004). Recent study of ischaemia and cancer in the same animal indicating that dose is not central to the anti-angiogenic effects of statins in carcinogenesis. This report alleviated concerns that clinically relevant doses of statins would promote tumour angiogenesis during treatment.
30. Kureishi, Y. et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nature Med 6, 1004-1010 (2000).
31. Parmar, K. M. et al. Statins exert endothelial atheroprotective effects via the KLF2 transcription factor. J. Biol. Chem. 280, 26714-26719 (2005).
32. Vincent, L. et al. Cerivastatin, an inhibitor of 3-hydroxy-3- methylglutaryl coenzyme a reductase, inhibits endothelial cell proliferation induced by angiogenic factors in vitro and angiogenesis in in vivo models. Arterioscler. Thromb. Vasc. Biol. 22, 623-629 (2002).
33. Skaletz-Rorowski, A. et al. HMG-CoA reductase inhibitors promote cholesterol-dependent Akt/PKB translocation to membrane domains in endothelial cells. Cardiovasc. Res, 57, 253-264 (2003).
34. Skaletz-Rorowski, A. & Walsh, K. Statin therapy and angiogenesis. Curr. Opin. Lipidol. 14, 599-603 (2003).
35. Urbich, C., Dernbach, E., Zeiher, A. M. & Dimmeler, S. Double-edged role of statins in angiogenesis signaling. Circ. Res. 90, 737-744 (2002).
36. Wu, J., Wong, W. W. L., Khosravi, F., Minden, M. D. & Penn, L. Z. Blocking the Raf-MEK-ERK pathway sensitizes acute myelogenous leukemia cells to lovastatin-induced apoptosis. Cancer Res. 64, 6461-6468 (2004).
37. Gniadecki, R. Depletion of membrane cholesterol causes ligand-independent activation of Fas and apoptosis. Biochem. Biophys. Res. Commun. 320, 165-169 (2004).
38. Shibata, M. A., Ito, Y., Morimoto, J. & Otsuki, Y. Lovastatin inhibits tumor growth and lung metastasis in mouse mammary carcinoma model: a p53-independent mitochondrial-mediated apoptotic mechanism. Carcinogenesis 25, 1887-1898 (2004).
39. Macaulay, R. J., Wang, W., Dimitroulakos, J., Becker, L. E. & Yeger, H. Lovastatin-induced apoptosis of human medulloblastoma cell lines in vitro. J. Neurooncol. 42, 1-11 (1999).
40. Marcelli, M. et al. Caspase-7 is activated during lovastatin-induced apoptosis of the prostate cancer cell line LNCaP. Cancer Res. 58, 76-83 (1998).
41. Cafforio, P., Dammacco, F., Gernone, A. & Silvestris, F. Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells. Carcinogenesis 26, 883-891 (2005).
42. Crick, D. C., Andres, D. A., Danesi, R., Macchia, M. & Waechter, C. J. Geranylgeraniol overcomes the block of cell proliferation by lovastatin in C6 glioma cells. J. Neurochem. 70, 2397-2405 (1998).
43. Jakobisiak, M., Bruno, S., Skierski, J. S. & Darzynkiewicz, Z. Cell cycle-specific effects of lovastatin. Proc. Natl Acad. Sci. USA 88, 3628-3632 (1991).
44. Park, C., Lee, I. & Kang, W. K. Lovastatin-induced E2F-1 modulation and its effect on prostate cancer cell death. Carcinogenesis 22, 1727-1731 (2001).
45. Maltese, W. A. & Sheridan, K. M. Differentiation of neuroblastoma cells induced by an inhibitor of mevalonate synthesis: relation of neurite outgrowth and acetylcholinesterase activity to changes in cell proliferation and blocked isoprenoid synthesis. J. Cell. Physiol. 125, 540-558 (1985).
46. Hentosh, P., Yuh, S. H., Elson, C. E. & Peffley, D. M. Sterol-independent regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase in tumor cells. Mol. Carcinogen. 32, 154-166 (2001).
47. Attoub, S. et al. Leptin promotes invasiveness of kidney and colonic epithelial cells via phosphoinositide 3-kinase-, Rho-, and Rac-dependent signaling pathways. FASEB J. 14, 2329-2338 (2000).
48. Agarwal, B. et al. Mechanism of Iovastatin-induced apoptosis in intestinal epithelial cells. Carcinogenesis 23, 521-528 (2002).
49. Erlinger, T. P., Platz, E. A., Rifai, N. & Helzlsouer, K. J. C-reactive protein and the risk of incident colorectal cancer. JAMA 291, 585-590 (2004).
50. Narisawa, T. et al. Chemoprevention by pravastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, of N-methyl-N-nitrosourea-induced colon carcinogenesis in F344 rats. Jpn. J. Cancer Res. 87, 798-804 (1996).
51. Agarwal, B. et al. Lovastatin augments sulindac-induced apoptosis in colon cancer cells and potentiates chemopreventive effects of sulindac. Gastroenterology 117, 838-847 (1999). Important, early preclinical study showing that statins reduced aberrant crypt foci, a clonal precursor of colorectal neoplasia, at the level of geranylgeranylation, and were synergistic with the NSAID sulindac in preventing aberrant crypt foci (see reference 48).
52. Rao, C. V., Newmark, H. L. & Reddy, B. S. Chemopreventive effect of farnesol and lanosterol on colon carcinogenesis. Cancer Detect. Prev. 26, 419-425 (2002).
53. Broitman, S. A., Wilkinson, J. T., Cerda, S. & Branch, S. K. Effects of monoterpenes and mevinolin on murine colon tumor CT-26 in vitro and its hepatic "metastases" in vivo. Adv. Exp. Med. Biol. 401, 111-130 (1996).
54. Swamy, M. V., Cooma, I., Reddy, B. S. & Rao, C. V. Lamin B, caspase-3 activity, and apoptosis induction by a combination of HMG-CoA reductase inhibitor and COX-2 inhibitors: a novel approach in developing effective chemopreventive regimens. Int. J. Oncol. 20, 753-759 (2002).
55. Feleszko, W. et al. Synergistic interaction between highly specific cyclooxygenase-2 inhibitor, MF-tricyclic and lovastatin in murine colorectal cancer cell lines. Oncol. Rep. 9, 879-885 (2002).
56. Reddy, B. S. et al. Synergistic effects of the combination of low doses of aspirin or celecoxib with Lipitor against colon carcinogenesis: a promising chemoprevention strategy. Proc. Amer. Assoc. Cancer. Res. 46, LB-4 (2005).
57. Solomon, S. D. et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N. Engl. J. Med. 352, 1071-1080 (2005).
58. Mueck, A. O., Seeger, H. & Wallwiener, D. Effect of statins combined with estradiol on the proliferation of human receptor-positive and receptor-negative breast cancer cells. Menopause 10, 332-336 (2003).
59. Seeger, H., Wallwiener, D. & Mueck, A. O. Statins can inhibit proliferation of human breast cancer cells in vitro. Exp. Clin. Endocrinol. Diabetes 111, 47-48 (2003).
60. Fritz, G., Brachetti, C., Bahlmann, F., Schmidt, M. & Kaina, B. Rho GTPases in human breast tumours: expression and mutation analyses and correlation with clinical parameters. Br. J. Cancer 87, 635-644 (2002).
61. Denoyelle, C. et al. Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study. Carcinogenesis 22, 1139-1148 (2001).
62. Wilde, C. & Aktories, K. The Rho-ADP-ribosylating C3 exoenzyme from Clostridium botulinum and related C3-like transferases. Toxicon. 39, 1647-1660 (2001).
63. Denoyelle, C. et al. Molecular mechanism of the anti-cancer activity of cerivastatin, an inhibitor of HMG-CoA reductase, on aggressive human breast cancer cells. Cell. Signal. 15, 327-338 (2003). An important preclinical study showing that cervistatin prevented RHOA prenylation and thereby inhibited RHOA-ROCK signalling. These findings support the idea that RHOA is an important target of statins in breast cancer prevention.
64. Silva, J., Beckedorf, A. & Bieberich, E. Osteoblast-derived oxysterol is a migration-inducing factor for human breast cancer cells. J. Biol. Chem. 278, 25376-25385 (2003).
65. Bourguignon, L. Y., Singleton, P. A., Zhu, H. & Diedrich, F. Hyaluronan-mediated CD44 interaction with RhoGEF and Rho kinase promotes Grb2-associated binder-1 phosphorylation and phosphatidylinositol 3-kinase signaling leading to cytokine (macrophage-colony stimulating factor) production and breast tumor progression. J. Biol. Chem. 278, 29420-29434 (2003).
66. Kumar, B. et al. Mevastatin induces degeneration and decreases viability of cAMP-induced differentiated neuroblastoma cells in culture by inhibiting proteasome activity, and mevalonic acid lactone prevents these effects. J. Neurosci. Res. 68, 627-635 (2002).
67. Murray, S. S., Tu, K. N., Young, K. L. & Murray, E. J. The effects of lovastatin on proteasome activities in highly purified rabbit 20 S proteasome preparations and mouse MC3T3-E1 osteoblastic cells. Metabolism 51, 1153-1160 (2002).
68. Wojcik, C. et al. Lovastatin and simvastatin are modulators of the proteasome. Intl J. Biochem. Cell. Biol. 32, 957-965 (2000).
69. Alonso, D. F. et al. Reduction of mouse mammary tumor formation and metastasis by lovastatin, an inhibitor of the mevalonate pathway of cholesterol synthesis. Breast Cancer Res. Treat. 50, 83-93 (1998).
70. Farina, H. G., Bublik, D. R., Alonso, D. F. & Gomez, D. E. Lovastatin alters cytoskeleton organization and inhibits experimental metastasis of mammary carcinoma cells. Clin. Exp. Metastasis 19, 551-559 (2002).
71. Esserman, L. et al. Breast cancer inhibition by statins. Proc. Am. Soc. Clin. Oncol. 23, 97 (2004).
72. Collisson, E. A., Carranza, D. C., Chen, I. Y. & Kolodney, M. S. Isoprenylation is necessary for the full invasive potential of RhoA overexpression in human melanoma cells. J. Invest. Dermatol. 119, 1172-1176 (2002).
73. Shellman, Y. G. et al. Lovastatin-induced apoptosis in human melanoma cell lines. Melanoma Res. 15, 83-89 (2005).
74. Collisson, E. A. et al. Atorvastatin prevents RhoC isoprenylation, invasion, and metastasis in human melanoma cells. Mol. Cancer Ther. 2, 941-948 (2003). A study providing a biological explanation for the significant secondary finding of a clinical trial, which showed that a statin reduced melanoma risk (see reference 104). This paper shows that RHOC is expressed in melanoma samples and that atorvastatin attenuated RHOC signalling and inhibited invasion and metastasis.
75. Busca, R. et al. Inhibition of Rho is required for cAMP-induced melanoma cell differentiation. Mol. Biol. Cell 9, 1367-1378 (1998).
76. Nakajima, M. et al. Effect of Wf-536, a novel ROCK inhibitor, against metastasis of B16 melanoma. Cancer Chemother. Pharmacol. 52, 319-324 (2003).
77. He, L., Mo, H., Hadisusilo, S., Qureshi, A. A. & Elson, C. E. Isoprenoids suppress the growth of murine B16 melanomas in vitro and in vivo. J. Nutr. 127, 668-674 (1997).
78. Lluria-Prevatt, M. et al. Effects of perillyl alcohol on melanoma in the TPras mouse model. Cancer Epidemiol. Biomarkers Prev. 11, 573-579 (2002).
79. Blais, L., Desgagne, A. & LeLorier, J. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study. Arch. Intern. Med. 160, 2363-2368 (2000).
80. Graaf, M. R., Beiderbeck, A. B., Egberts, A. C., Richel, D. J. & Guchelaar, H. J. The risk of cancer in users of statins. J. Clin. Oncol. 22, 2388-2394 (2004). A large prospective observational study showing a significant reduction in overall cancer risk (and non-significant reductions in colorectal and prostate cancer) associated with statins. This study is therefore an important contribution to the current focus on statins for cancer prevention.
81. Kaye, J. A. & Jick, H. Statin use and cancer risk in the General Practice Research Database. Br. J. Cancer 90, 635-637 (2004).
82. Kaye, J. A., Meier, C. R., Walker, A. M. & Jick, H. Statin use, hyperlipidaemia, and the risk of breast cancer. Br. J. Cancer 86, 1436-1439 (2002).
83. Friis, S. et al. Cancer risk among statin users: a population-based cohort study. Int. J. Cancer 114, 643-647 (2005).
84. Platz, E. A. et al. Cholesterol-lowering drugs including statins and the risk of prostate cancer in a large prospective cohort study. Proc. Am. Assoc. Cancer Res. 46, 1034 (2005).
85. Shannon, J et al. Statins and prostate cancer risk: a case control study. Am. J. Epidemiol. 162, 318-325 (2005).
86. Singal, R., Khurana, V., Caldito, G. & Fort, C. Statins and prostate cancer risk: a case control study. Am. J. Epidemiol. 162 318-325 (2005).
87. Shibata, M. A. et al. Comparative effects of lovastatin on mammary and prostate oncogenesis in transgenic mouse models. Carcinogenesis 24, 453-459 (2003).
88. Poynter, J. N. et al. Statins and the risk of colorectal cancer. N. Engl. J. Med. 352, 2184-2192 (2005). Large population-based case-control study showing the strong inverse association between colorectal cancer and long-term statin use, solidifying the potential importance of statins for preventing colorectal cancer.
89. Wei, J. T. et al. Reported use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors was not associated with reduced recurrence of colorectal adenomas. Cancer Epidemiol. Biomarkers Prev. 14, 1026-1027 (2005).
90. Beck, P., Wysowski, D. K., Downey, W. & Butler-Jones, D. Statin use and the risk of breast cancer. J. Clin. Epidemiol. 56, 280-285 (2003).
91. Cauley, J. A. et al. Lipid-lowering drug use and breast cancer in older women: a prospective study. J. Womens Health (Larchmt) 12, 749-756 (2003).
92. Coogan, P. F. et al. Statin use and the risk of breast and prostate cancer. Epidemiology 13, 262-267 (2002).
93. Boudreau, D. M. et al. The association between 3-hydroxy-3-methylglutaryl conenzyme A inhibitor use and breast carcinoma risk among postmenopausal women: a case-control study. Cancer 100, 2308-2316 (2004).
94. Dellavalle, R. P., Nicholas, M. K. & Schilling, L. M. Melanoma chemoprevention: a role for statins or fibrates? Am. J. Ther. 10, 203-210 (2003).
95. Khurana, V., Kochhar, R., Bejjanki, H. R. & Fort, C. Statins reduce the incidence of lung cancer: a study of half a million U. S. veterans. Proc. Am. Soc. Clin. Oncol. 16 (Suppl.), 1006 (2005).
96. Khurana, V., Barkin, J. S., Caldito, G. & Fort, C. Statins reduce the risk of pancreatic cancer in humans: half a million US veterans' case control study. Gastroenterol. 128 (Suppl.), A62-A62 (2005).
97. Khurana, V., Chalasani, R., Caldito, G. & Fort, C. Statins reduce the incidence of esophageal cancer: a study of half a million US veterans. Gastroenterol. 128 (Suppl.), A93-A93 (2005).
98. Zhang, Y. et al. Prior medical conditions and medication use and risk of non-Hodgkin lymphoma in Connecticut United States women. Cancer Causes Control 15, 419-428 (2004).
99. Fortuny, J. et al. Statin use and risk of lymphoma. Results from the European case-control study Epilymph. 9th International Conference on Malignant Lymphoma, Lugano, Switzerland, 8 June, 2005.
100. Duncan, R.E. et al. Statins and cancer development. Cancer Epidemiol. Biomarkers Prev. 14, 1897-1898 (2005).
101. Strandberg, T. E. et al. Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet 364, 771-777 (2004). Longest follow-up analysis of any RCT (in CVD prevention), showing a significant overall mortality benefit of statins and non-significant benefits in cancer risk and mortality over 10 years. This analysis supports the feasibility of statins for long-term cancer prevention.
102. Shepherd, J. et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med. 333, 1301-1307 (1995).
103. Sacks, F. M. et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N. Engl. J. Med. 335, 1001-1009 (1996).
104. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. J. Med. 339, 1349-1357 (1998).
105. Downs, J. R. et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279, 1615-1622 (1998). First RCT showing a secondary benefit of statins in cancer risk reduction. This benefit, a significant reduction in melanoma, helped overcome suspicions that statins had adverse cancer effects and promotes belief in the potential of statins to prevent melanoma and other cancers.
106. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360, 7-22 (2002).
107. Shepherd, J. et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360, 1623-1630 (2002).
108. Pfeffer, M. A. et al. Safety and tolerability of pravastatin in long-term clinical trials: Prospective Pravastatin Pooling (PPP) project. Circulation 105, 2341-2346 (2002).
109. Hebert, P. R., Gaziano, J. M., Chan, K. S. & Hennekens, C. H. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA 278, 313-321 (1997).
110. Bjerre, L. M. & LeLorier, J. Do statins cause cancer? A meta-analysis of large randomized clinical trials. Am. J. Med. 110, 716-723 (2001).
111. Guallar, E. & Goodman, S. N. Statins and cancer: a case of meta-uncertainty. Am. J. Med. 110, 738-740 (2001).
112. Weitz-Schmidt, G. Statins as anti-inflammatory agents. Trends Pharm. Sci. 23, 482-486 (2002).
113. Jakobisiak, M. & Golab, J. Potential antitumor effects of statins. Intl J. Oncol. 23, 1055-1069 (2003).
114. Graaf, M. R., Richel, D. J., van Noorden, C. J. F. & Guchelaar, H. H. J. Effects of statin and farnesyltransferase inhibitors on the development and progression of cancer. Cancer Treat. Rev. 30, 609-641 (2004).
115. Caraglia, M. et al. Isoprenylation of intracellular proteins as a new target for the therapy of human neoplasms: preclinical and clinical implications. Curr. Drug Targets 6, 301-323 (2005).
116. Rowinsky, E. K, Windle J. J. & Von Hoff, D. D. Ras protein farnesyltransferase: a strategic target for anticancer therapeutic development. J. Clin. Oncol. 17, 3631-3652 (1999).
117. Liao, J. K. et al. Pleiotropic effects of statins. Annu. Rev. Pharmacol. Toxicol. 45, 89-118 (2005).
118. Pillé, J. Y. et al. Anti-RhoA and anti-RhoC siRNAs inhibit the proliferation and invasiveness of MDA-MB-231 breast cancer cells in vitro and in vivo. Mol. Ther. 11, 267-274 (2005).
119. Wang, C. et al. Identification of FBL2 as a geranylgeranylated cellular protein required for hepatitis C virus RNA replication. Mol. Cell 18, 425-434 (2005).
120. Winter-Vann, A. M. et al. A small-molecule inhibitor of isoprenylcysteine carboxyl methyltransferase with antitumor activity in cancer cells. Proc. Natl Acad. Sci. USA 102, 4336-4341 (2005). An important recent study by this investigative group, highlighting the potential importance of a post-prenylation enzyme target for potential anticancer drugs.
121. Anderson, J. L., Henriksen, B. S., Gibbs, R. A. & Hrycyna, C. A. The isoprenoid substrate specificity of isoprenylcysteine carboxylmethyltransferase: development of novel inhibitors. J. Biol. Chem. 280, 29454-29461 (2005).
122. Weitz-Schmidt, G., Welzenbach, K., Dawson, J. & Kallen, J. Improved lymphocyte function-associated antigen-1 (LFA-1) inhibition by statin derivatives: molecular basis determined by x- X-ray analysis and monitoring of LFA-1 conformational changes in vitro and ex vivo. J. Biol. Chem. 279, 46764-46771 (2004).
123. Subdo, J. et al. Non-steroidal anti-inflammatory drugs and the risk of oral cancer: a nested case-control study. Lancet 366, 1359-1366 (2005).
124. Mantha, A. J. et al. Targeting the mevalonate pathway inhibits the function of the epidermal growth factor receptor. Clin. Cancer Res. 11, 2398-2407 (2005).
125. Hawk, E. & Viner, J. L. Statins and cancer - beyond the "one drug, one disease" model. N. Engl. J. Med. 352, 2238-2239 (2005).
126. Topol, E. J. Intensive statin therapy - a sea change in cardiovascular prevention. N. Engl. J. Med. 350, 1562-1564 (2004).
127. Lippman, S. M. & Hong, W. K. Cancer prevention science and practice. Cancer Res. 62, 5119-5125 (2002).